9 results
1. To assess serum calcification propensity (T50) in SSc patients compared with healthy age and gender-matched controls; 2. To assess serum T50 in SSc patients with overt calcinosis cutis as compared to age and gender-matched SSc patients without; 3…
Primary objective:• To assess the safety and feasibility of adding ipilimumab-nivolumab to a CRT induction protocol• To assess the efficacy of adding ipilimumab-nivolumab to CRT on the likelihood of a pCR and MPRSecondary objectives: • Local and…
The purpose of this study is to determine the safety and efficacy of post-surgery treatment with the monoclonal antibody ipilimumab, to see whether treatment improves recurrence-free survival (RFS), overall survival and distant metastases-free…
The primary objective is to determine the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of BMS-986178 administered alone or in combination with nivolumab and/or ipilimumab in…
The objective of this study is to determine how well two different doses of ipilimumab work in patients with prostate cancer who are no longer responding to hormone therapy (castration resistant), and whom have the best radiographic progression-…
The objective of this study is to investigate the mechanism(s) of action of tirzepatide in the kidney, in participants who are overweight or living with obesity and coexisting CKD, with and without T2D, to inform potential future kidney outcomes…
Primary Objectives - To compare Overall Survival (OS) and Progression free survival (PFS) of nivolumab monotherapy to ipilimumab monotherapy and that of nivolumab combined with ipilimumab to ipilimumab monotherapy in subjects with previously…
The main reason for conducting this study is to help in answering the following research question:• How tirzepatide compares to dulaglutide in preventing cardiovascular events in participants with type 2 diabetes and a higher risk of cardiovascular…
Primary objectiveTo determine the pathological complete response rate per cohort